{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:01:48Z","timestamp":1773219708414,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.amjcard.2015.09.026","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T21:43:34Z","timestamp":1444081414000},"page":"1840-1844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)"],"prefix":"10.1016","volume":"116","clinical-trial-number":[{"clinical-trial-number":"nct00092677","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Casper N.","family":"Bang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders M.","family":"Greve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"La Cour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Boman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Gohlke-B\u00e4rwolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terje","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Rosseb\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Okin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Wachtell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2015.09.026_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.6822","article-title":"Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease","volume":"314","author":"Pandya","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.09.026_bib2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.09.026_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11886-013-0461-4","article-title":"Statin treatment, new-onset diabetes, and other adverse effects: a systematic review","volume":"16","author":"Bang","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.amjcard.2015.09.026_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00041433-199912000-00010","article-title":"Low-density lipoprotein-independent effects of statins","volume":"10","author":"Davignon","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.annepidem.2009.10.007","article-title":"Persistence with statins and incident cataract: a population-based historical cohort study","volume":"20","author":"Chodick","year":"2010","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ajo.2006.11.027","article-title":"Statin use and the long-term risk of incident cataract: the Blue Mountains Eye study","volume":"143","author":"Tan","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib7","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1001\/jama.295.23.2752","article-title":"Statin use and incident nuclear cataract","volume":"295","author":"Klein","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.09.026_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.diabet.2010.09.005","article-title":"Statin therapy and cataract in type 2 diabetes","volume":"37","author":"Hermans","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjcard.2015.09.026_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2015.09.026_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/2047487312462804","article-title":"Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study","volume":"21","author":"Bang","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib11","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2015.09.026_bib12","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/bjo.79.11.996","article-title":"Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group","volume":"79","author":"Harris","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0002-9149(91)90002-3","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin","volume":"67","author":"Laties","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.09.026_bib15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study","volume":"99","author":"Rossebo","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib16","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjcard.2015.09.026_bib17","series-title":"Clinical Ophthalmology: A Sytematic Approach","author":"Kanski","year":"2011"},{"key":"10.1016\/j.amjcard.2015.09.026_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archopht.1988.01060130363022","article-title":"Antioxidant status in persons with and without senile cataract","volume":"106","author":"Jacques","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/archopht.1991.01080020090051","article-title":"The lens opacities case-control study. Risk factors for cataract","volume":"109","author":"Leske","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib20","first-page":"541","article-title":"Risk factors for age-related cortical, nuclear, and posterior subcapsular cataracts. The Italian-American Cataract Study Group","volume":"133","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archopht.119.10.1439","article-title":"A\u00a0randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study","volume":"108","author":"Kinlay","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.09.026_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.09.026_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","volume":"131","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/qjmed\/hcg064","article-title":"Cataract and the use of statins: a case-control study","volume":"96","author":"Smeeth","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.amjcard.2015.09.026_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0749-3797(18)30763-3","article-title":"Cigarette smoking and lens opacities: the Beaver Dam Eye Study","volume":"9","author":"Klein","year":"1993","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.amjcard.2015.09.026_bib27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-9394(14)70223-5","article-title":"Hypertension and lens opacities from the Beaver Dam Eye Study","volume":"119","author":"Klein","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/OPX.0b013e3182644cd1","article-title":"Age-related cataract is associated with type 2 diabetes and statin use","volume":"89","author":"Machan","year":"2012","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.amjcard.2015.09.026_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0039-6257(96)82007-8","article-title":"Cholesterol and cataracts","volume":"40","author":"Cenedella","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.amjcard.2015.09.026_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/aje\/kws279","article-title":"High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: a population-based prospective cohort study of men","volume":"177","author":"Zheng","year":"2013","journal-title":"Am J Epidemiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915020056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915020056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T07:22:05Z","timestamp":1567236125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914915020056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0002914915020056"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.09.026","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}